SCHEMBL7204369

SCHEMBL7204369

Cc1ccc(C(=O)O)cc1C#CCCCO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ CYP1A2 P05177 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ RARB P10826 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MYC P01106 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ PTPN7 P35236 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203454 0.90 RARB (0.40) TSHRALDH1A1CYP1A2KDM4ECYP2C9
SCHEMBL6785258 0.85 ALDH1A1 (0.49) TSHRALDH1A1KDM4ECYP2C9MAPT
SCHEMBL3420562 0.81 TSHR (0.42) TSHRALDH1A1CYP1A2KDM4EMAPT
SCHEMBL6297936 0.80 ALDH1A1 (0.42) TSHRALDH1A1CYP1A2KDM4ECYP2C9
SCHEMBL31281492 0.77 ALDH1A1 (0.41) ALDH1A1CYP1A2KDM4ECYP2C9CYP3A4
SCHEMBL20500276 0.77 ALDH1A1 (0.41) ALDH1A1CYP1A2KDM4ECYP2C9CYP3A4
SCHEMBL6788689 0.77 PTGDR2 (0.44) ALDH1A1CYP1A2KDM4ECYP2C9CYP3A4
SCHEMBL6785176 0.76 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTHPGDGAA
SCHEMBL10454531 0.76 CYP3A4 (0.57) TSHRALDH1A1CYP1A2KDM4ECYP2C9
SCHEMBL28049640 0.76 TSHR (0.46) TSHRALDH1A1CYP1A2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605628-B1 Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis WYETH HOLDINGS CORPORATION 2003-08-12 — — US disclosed
Send feedback